Search Results

Business

Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease

Viridian Therapeutics, Inc. and Ypsomed AG (SIX: YPSN), the leading developer and manufacturer of injection and infusion systems for self-medication have signed a supply agreement for Ypsomed’s customizable YpsoMate 2.25 autoinjector pen device with a fill volume of 2.0 milliliters.

October 26, 2023

·

7 min read

Press Releases

MTD Group completes the acquisition of Ypsomed’s Pen Needles and Blood Glucose Monitoring Systems and announces a significant investment plan for its European production sites

August 2, 2024

·

4 min read

Business

Civica Welcomes Ypsomed as Injection Pen Partner for Its Affordable Insulin Initiative

Civica, Inc. (Civica, Civica Rx) today announced the selection of Ypsomed AG as the manufacturer and supplier of insulin dosing injector pens for Civica’s affordable insulins.

January 31, 2023

·

2 min read

Job Trends

Abbott, CamDiab and Ypsomed Unveil New Automated Insulin Delivery Partnership for People with Diabetes

Abbott (NYSE: ABT), CamDiab and Ypsomed today announced that they are partnering to develop and commercialize an integrated automated insulin delivery (AID) system to help lessen the burden of round-the-clock diabetes management for people with diabetes.

April 27, 2022

·

4 min read

Business

Lilly and Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes

Eli Lilly and Company (NYSE: LLY) and Ypsomed (SWX: YPSN) announced today a non-exclusive, global agreement to advance an automated insulin delivery system as part of Lilly’s connected diabetes solutions.

November 19, 2020

·

5 min read

Job Trends

Abbott’s FreeStyle Libre® 3 Integrated with Automated Insulin Delivery System mylife™ Loop in Germany

Abbott (NYSE: ABT) today announced that its FreeStyle Libre® 3 sensor is now compatible with the mylife™ Loop solution from partners, Ypsomed and CamDiab, creating a smart, automated process to deliver insulin based on real-time glucose data.

December 21, 2022

·

3 min read

Business

LANNETT ANNOUNCES PATENT LICENSES FOR THE PEN INJECTOR DELIVERY DEVICE TO BE USED FOR ITS INSULIN GLARGINE AND INSULIN ASPART DEVELOPMENT PROGRAM

Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Ypsomed AG, the manufacturer and supplier of the pen injector device to be used in connection with its biosimilar insulin glargine and biosimilar insulin aspart development programs.

November 7, 2022

·

3 min read

Business

Bigfoot Biomedical and Ypsomed Announce Agreement

Bigfoot Biomedical and Ypsomed announced that the companies have entered into an agreement under which Ypsomed will supply Bigfoot with a customized proprietary version of its Orbit infusion sets as part of Bigfoot’s investigational automated insulin pump-based solution for use in a pivotal trial.

October 24, 2017

·

3 min read

Business

Ypsomed Tanks as Insulet Decides Not to Extend Omnipod Agreement in 2018

July 21, 2017

·

7 min read

Policy

LEM Surgical AG Secures CHF 22 Million in Series B Funding to Ready Robotic System for FDA Submission

LEM Surgical AG, an innovative surgical robotics company headquartered in Bern, Switzerland, announces the successful completion of its Series B funding, securing CHF 22 million.

January 4, 2024

·

1 min read